Cipher Pharmaceuticals Inc.
TSX:CPH.TO · Toronto Stock Exchange
+$0.15 today
Vol 0.01M · Avg 0.03M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:CPH.TO · Revenue to Net Income
Key Ratios
Analysis
$50.9M of revenue converted into $31.0M of net income for the selected period. Gross margin is 74.3% and net margin is 61.3%, showing how much revenue survives after costs and taxes. EPS is $1.19, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.3M +53.9% | $33.4M +57.7% | $21.2M +2.4% | $20.7M -5.8% | $21.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $17.6M +89.7% | $9.3M +127.6% | $4.1M +1.9% | $4.0M +8.4% | $3.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.8M +40.1% | $24.1M +41.0% | $17.1M +2.5% | $16.7M -8.6% | $18.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 65.8% -6.5pp | 72.2% -8.5pp | 80.8% +0.1pp | 80.7% -2.5pp | 83.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.4K | $0 -100.0% | $139.0K +41.8% | $98.0K +11.4% | $88.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $16.3M +33.2% | $12.2M +125.6% | $5.4M +23.3% | $4.4M -13.9% | $5.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $17.0M +4.4% | $16.3M +192.1% | $5.6M -1.2% | $5.6M -12.7% | $6.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $7.2M +80.0% | $4.0M +227.4% | $1.2M +24.1% | $989.0K +41.1% | $701.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $24.1M +103.1% | $11.9M +2.9% | $11.5M -4.2% | $12.0M -11.9% | $13.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 46.9% +11.4pp | 35.6% -18.9pp | 54.5% -3.8pp | 58.2% -4.0pp | 62.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $16.8M +114.1% | $7.8M -31.9% | $11.5M -4.2% | $12.0M +1.8% | $11.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 32.7% +9.2pp | 23.5% -31.0pp | 54.5% -3.8pp | 58.2% +4.4pp | 53.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $330.0K -82.4% | $1.9M +303.0% | $464.0K +3766.7% | $12.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.2M | $0 | $0 | $0 -100.0% | $92.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $661.4K +113.5% | -$4.9M -524.7% | $1.2M +305.7% | -$560.0K +72.0% | -$2.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $17.5M +491.0% | $3.0M -76.7% | $12.7M +10.5% | $11.5M +3.8% | $11.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 34.0% +25.2pp | 8.9% -51.1pp | 59.9% +4.4pp | 55.5% +5.1pp | 50.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$10.3M -20.4% | -$8.6M -11.5% | -$7.7M +49.2% | -$15.2M -559.2% | $3.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $27.8M +140.9% | $11.5M -43.4% | $20.4M -23.5% | $26.6M +243.3% | $7.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 54.2% +19.6pp | 34.6% -61.7pp | 96.3% -32.5pp | 128.8% +93.5pp | 35.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +131.9% | $0 -41.3% | $1 -24.5% | $1 +265.5% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +127.7% | $0 -41.3% | $1 -23.1% | $1 +258.6% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $25.5M +3.1% | $24.7M -3.0% | $25.5M +1.4% | $25.1M -5.5% | $26.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $26.0M +5.8% | $24.6M -3.4% | $25.4M -0.6% | $25.6M -4.6% | $26.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Knight Therapeutics Inc.
TSX:GUD.TO
$922.89M
NervGen Pharma Corp.
NGEN.V
$407.94M
Spectral Medical Inc.
TSX:EDT.TO
$399.05M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$360.97M
High Tide Inc.
HITI.V
$289.97M
TerrAscend Corp.
TSX:TSND.TO
$283.25M
Canopy Growth Corporation
TSX:WEED.TO
$243.53M
Aurora Cannabis Inc.
TSX:ACB.TO
$233.64M
OrganiGram Holdings Inc.
TSX:OGI.TO
$189.69M
Jushi Holdings Inc.
JUSH.CN
$129.80M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CPH.TO generate?
Cipher Pharmaceuticals Inc. (CPH.TO) reported $51.33M of revenue in fiscal 2025.
Is CPH.TO profitable?
Cipher Pharmaceuticals Inc. (CPH.TO) reported $27.81M of net income, with a net margin of 54.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.